Prognostic markers in diffuse large B-cell lymphoma: Keys to the underlying biology

Jane N. Winter*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

3 Scopus citations


Prognostic markers identify subgroups of patients with similar risk profiles, helping to guide clinical care. The addition of rituximab to conventional anthracycline-based chemotherapy has improved clinical outcomes for patients with diffuse large B-cell lymphoma (DLBCL). Studies suggest that rituximab eliminates or modulates the significance of some markers (eg, BCL6 or BCL2), whereas other previously unimportant markers may emerge as significant prognostic indicators in the setting of treatment that now includes rituximab. These changes in the prognostic profile are likely to reflect the impact of rituximab on survival pathways important to some groups of patients with DLBCL but not to other groups, and thereby may provide clues to the underlying biology of the disease. They also identify subgroups of patients likely to benefit most from rituximab therapy and those who seem to garner no advantage from its inclusion in their treatment. Studies of prognostic indicators in the context of modern therapy have the potential to identify new, rational therapeutic targets for this biologically diverse disease.

Original languageEnglish (US)
Pages (from-to)235-241
Number of pages7
JournalCurrent Hematologic Malignancy Reports
Issue number4
StatePublished - Dec 2007

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research


Dive into the research topics of 'Prognostic markers in diffuse large B-cell lymphoma: Keys to the underlying biology'. Together they form a unique fingerprint.

Cite this